Black­Rock push­es Ex­sci­en­tia Se­ries C to $100M as AI biotech boom con­tin­ues

The ju­ry’s still out on whether the first wave of AI com­pa­nies can sig­nif­i­cant­ly change drug de­vel­op­ment, but in­vestors are in­creas­ing­ly buy­ing in­to the hype.

Ex­sci­en­tia, the decade-old UK ma­chine learn­ing out­fit, an­nounced Thurs­day that they’ve ex­pand­ed their Se­ries C, first an­nounced in May, from $60 mil­lion to $100 mil­lion. The ex­pan­sion most no­tably in­cludes Black­Rock, the pri­vate eq­ui­ty firm that has been wad­ing deep­er and deep­er in­to biotech. They now join No­vo Hold­ings, Bris­tol My­ers Squibb and oth­ers among the com­pa­ny’s most re­cent back­ers.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER